SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?


To: Rocketman who wrote (4915)5/15/1998 12:49:00 PM
From: Rocketman  Respond to of 9719
 
RESEARCH ALERT - Genzyme buy repeated

Friday May 15, 10:53 am Eastern Time

CHICAGO, May 15 (Reuters) - Madison Securities on Friday said it repeated a buy rating on Genzyme General Corp. with 12 and 18 month price targets
of $38 and $43 a share.

In a research report, Madison Securities analyst Sharon Doering said she expects Genzyme's new products to accelerate sales significantly in the 1998
second half.

Genzyme provides specialty therapeutics, and surgical and diagnostic products.



To: Rocketman who wrote (4915)5/15/1998 7:52:00 PM
From: Cytokine1  Respond to of 9719
 
I think it might deflate back down to the 5 or 6 area. 'Course one never knows with all these cancer cures flying around. *)